前列腺癌大分割放疗不良反应的临床证据与缓解策略
本文系统综述了截至2025年6月的III期随机试验,评估前列腺癌大分割放疗的毒性结局与缓解策略。运动管理和缩小边界可使SBRT后≥2级毒性减半。
要点
- 中度大分割放疗晚期≥2级泌尿生殖毒性达12-46%,SBRT后12-24个月出现毒性高峰
- 基线IPSS较高可能预测MHRT和SBRT后的晚期≥2级泌尿生殖毒性
- 运动管理和缩小边界使前列腺癌SBRT后≥2级毒性减半
核心结论
- 大分割放疗试验中≥2级泌尿生殖毒性仍然常见,缓解策略对强化放疗方案的持续发展至关重要。
- 运动管理和缩小边界是减少前列腺癌SBRT后严重毒性的有前景方法,值得纳入临床实践和未来试验设计。
主要发现
- 等剂量和剂量递增中度大分割放疗的晚期≥2级泌尿生殖毒性发生率分别为12-46%和15-45%。
- 立体定向体部放疗后12至24个月观察到≥2级泌尿生殖毒性高峰,导致5年累积发生率更高。
- 基线IPSS较高被提示可预测中度大分割放疗和立体定向体部放疗后的晚期≥2级泌尿生殖毒性。
- 中度大分割放疗似乎不影响晚期胃肠道毒性,等剂量和剂量递增组的晚期≥2级毒性发生率分别为8.9-25%和12.7-23.8%。
- 通过运动管理策略缩小边界使前列腺癌立体定向体部放疗后≥2级毒性发生率减半。
关键数值与推荐
- 晚期≥2级泌尿生殖毒性:等剂量中度大分割放疗为12-46%,剂量递增为15-45%。
- 晚期≥2级胃肠道毒性:等剂量中度大分割放疗为8.9-25%,剂量递增为12.7-23.8%。
临床怎么用
- 当前缓解策略包括最小化危及器官剂量、延长总治疗时间以及基于个体放射敏感性进行个性化治疗。
- 运动管理和缩小边界应纳入临床实践和未来临床试验设计以减少SBRT后严重毒性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The technical advances allowed to take the leap towards hypofractionated schedules, as well as dose-escalated schedules, for prostate cancer (PCa) radiotherapy (RT). The aim of this systematic review is to describe RT techniques and toxicity outcomes within trials investigating hypofractionation, and to discuss current or future strategies to mitigate treatment-related toxicity. METHODS: We searched Pubmed database until June, 2025. Studies deemed eligible were phase III trials randomizing different type of fractionation (with at least one arm using hypofractionation) for PCa RT. RESULTS: Thirty-two articles were included. Rates of late grade≥2 genitourinary (GU) toxicity ranged between 12-46% and 15-45% for patients receiving isodose and dose-escalated moderately hypofractionated radiotherapy (MHRT). A flare of grade≥2 GU toxicity was observed 12 to 24 months following stereotactic body radiotherapy (SBRT), translating into a higher cumulative incidence of grade≥2 GU toxicity at 5 years. Higher IPSS at baseline was suggested to be predictive of late grade≥2 GU toxicity following both MHRT and SBRT. Overall, MHRT does not seem to negatively impact late gastrointestinal (GI) toxicity, with rates of late grade≥2 toxicity ranging between 8.9-25% and 12.7-23.8% for isodose and dose-escalated MHRT. Current mitigation strategies include minimizing the dose delivered to organs at risk (OARs), prolonging overall treatment time, and personalizing treatments based on individual radiosensitivity. Among the strategies allowing for a reduction of the dose to adjacent OARs, margin reduction achieved through motion management strategies halved the rates of grade≥2 toxicity following PCa SBRT. CONCLUSIONS: Grade≥2 GU toxicity remains frequent in trials testing hypofractionation. Mitigation strategies are therefore critical to the continued evolution of intensified RT regimens. Motion management and margin reduction are particularly promising approaches to reduce severe toxicity after PCa SBRT, warranting their incorporation into clinical practice and future clinical trial designs.
引用
- Le Guevelou J, Zilli T, Ferrario F, et al. Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies. Prostate Cancer Prostatic Dis. 2025. PMID: 41437135. doi:10.1038/s41391-025-01071-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。